GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Dabrafenib (Tafinlar), oral capsule

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Tafinlar - labeled renal guidance

Product / population
Dabrafenib (Tafinlar), oral capsule
Renal method
Indexed GFR/eGFR, mL/min/1.73 m2
Source revision
DailyMed SPL version 37, posted May 21, 2026
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Tafinlar - product and source limitations

The analysis supplies no dialysis schedule. Check the regimen and combination partner.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Tafinlar - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Dabrafenib (Tafinlar), oral capsule

Renal method: Indexed GFR/eGFR, mL/min/1.73 m2
Source date: DailyMed SPL version 37, posted May 21, 2026
Retrieved: 2026-11-07

Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 12.3 Pharmacokinetics

Dabrafenib pharmacokinetics showed no clinically important difference at eGFR 15-89 mL/min/1.73 m2. The analysis supplies no dialysis schedule. Check the regimen and combination partner.

RDM74-tafinlar-official-1 · Source locator: Renal guidance: 12.3 Pharmacokinetics

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea
Retrieved
2026-11-07
Renal-function method
Indexed GFR/eGFR, mL/min/1.73 m2
Source date/version
DailyMed SPL version 37, posted May 21, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
77e9d19d7d9d74c47002f35203d2bf6f75f8252b9c783732ade2a22262a1f563

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-tafinlar&s1=RDM74-tafinlar-official&h1=c590a7fcddad7fa053cccd8602b66133571e23b3a83cfa7064f43f314b821661

Top